On August 19, AbbVie rose 3.04% in regular trading, trading at $266.83/share, with turnover of $816 million. The rally was driven by a wave of Wall Street price target upgrades and continued pipeline momentum.

On the analyst front, Wolfe upgraded AbbVie to Outperform and set a $300 price target, while Wells Fargo raised its target to $300 maintaining an Overweight rating. Barclays lifted its target to $300, JPMorgan to $285, and Bank of America to $276. The FactSet consensus mean target has risen to approximately $278.73.

On the pipeline side, AbbVie recently registered a global Phase III clinical trial for RC148, a PD-1/VEGF bispecific antibody licensed from RemeGen, in a head-to-head study against pembrolizumab plus chemotherapy for first-line non-small cell lung cancer, marking the asset's entry into late-stage development and further enriching the company's oncology portfolio.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)